Histogen Inc
OTC:HSTOQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (0.3), the stock would be worth $0 (36% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.5 | $0 |
0%
|
| 3-Year Average | 0.3 | $0 |
-36%
|
| 5-Year Average | 0.2 | $0 |
-56%
|
| Industry Average | 15.1 | $0.04 |
+3 234%
|
| Country Average | 23.2 | $0.06 |
+5 034%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Histogen Inc
OTC:HSTOQ
|
10k USD | 0.5 | -0 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 184.9 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 24 | 88.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 27 | 23 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 18.4 | 19.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.1 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 31.3 | 27.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 14.1 | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 142.2 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -64.3 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 20.6 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.4 |
| Median | 23.2 |
| 70th Percentile | 35.1 |
| Max | 3 178 983.5 |
Other Multiples
Histogen Inc
Glance View
Histogen, Inc. engages in the development of potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The company is headquartered in San Diego, California and currently employs 22 full-time employees. The company went IPO on 2013-07-25. The firm is focused on developing its hypoxia-generated growth factor technology platform and stem cell-free biologic products as restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The firm's product pipelines include CCM Cosmetics, HST 003, HST 004, and Emricasan. In addition, within its small molecule pipeline, its product candidates also include CTS-2090 and CTS-2096. Its HST-003 is a human extracellular matrix (hECM), which is focused on regenerating hyaline cartilage for the treatment of articular cartilage defects in the knee, with a malleable scaffold that stimulates the body’s own stem cells. HST 004 is a cell conditioned medium (CCM) solution, which is used for treatment of spinal disc repair. Emricasan is an orally active pan-caspase inhibitor being developed for the treatment of COVID-19.
